The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Until we see what the value of StemPrintER after the meeting on the 29th May people can speculate what the value might be. No forth coming evaluation was give only that it is presently at "zero book value" . Tuesday will be interesting to see if the sp stalls and waits for the decision.
Do I want to hold new StemPrintER as a separate stock on the LSE and a devalued Tiziana Life Sc on day one or wait until the stock is split and buy into Tiziana Life Sc.?What will be the value and devaluation of Tiziana Life Sc when the split occurs?
AT least we can back up our arguments or points of view with facts. Meanwhile Zeb just sings mud.
TILS is with the 2 big company Covid-19 treatments, and TILS has already shown 2 distinct advantages over Roche's Actemra and Regeneron’s Kevzara. Hence why TILS has had to file the patent for this treatment very quickly. They have a major competitive advantage going forward - and none of this has been reflected in the previously over sold prices.
The recent news is that Ventilators are causing permanent lung damage, because they are forcing oxygen in, which is not being totally used by the lungs due to the lung infection. Therefore the infection has to be cleared or the patience dies. TILS targeting drug and procedure (superior) and targets the lungs to clear the infection that is actually causing death. :) / this is home run, considering to major drugs have worked in China and these are intravenous delivery only and do not deliver directly to the lungs. They also caused poor immune responses because they’re humanised and not like TILS drug which is human ready and will not have any impact on human immune system.
TZLS-501 by Tiziana Life Sciences
Tiziana Life Sciences is developing its monoclonal antibody named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6.
The drug works by binding to IL-6R and depleting the amount of IL-6 circulating in the body thereby reducing chronic lung inflammation.
Actemra by Roche to treat coronavirus-related complications
China approved the use of Roche’s Actemra for the treatment of severe complications related to coronavirus. Drugs like Actemra have the ability to prevent cytokine storms or overreaction of the immune system, which is considered as the main reason behind organ failure leading to death in some coronavirus patients.
Actemra is also being evaluated in a clinical trial in China, which is expected to enrol 188 coronavirus patients. The clinical trial is expected to be conducted until May 10.
Regeneron’s REGN3048-3051 and Kevzara
Discovered by Regeneron, the combination of neutralising monoclonal antibodies REGN3048 and REGN3051 is being studied against coronavirus infection in a first-in-human clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The safety and tolerability of the drug will be studied in 48 patients.
Both the antibodies bind to S-protein of MERS coronavirus. The intravenous administration of the drug in the mouse model of MERS resulted in the high-level neutralisation of the MERS coronavirus in circulating blood with reduced viral loads in the lungs.
Regeneron has partnered with Sanofi to evaluated Kevzara, a fully-human monoclonal antibody, in a phase two/three clinical trial in patients with severe COVID-19 infection. Kevzara is approved for the treatment of rheumatoid arthritis and is known t
poor outcome TILS £3 with STEM £3 as a whole £6 within 12month
best outcome TILS £5-7 with STEM buyout around $2.5 or $3billion
It is possible that zebbo is just giving a slightly more balanced view to the future outcome. I'd love to see £10 a share price but how many people are now expecting that as a minimum and will be upset if it dosent reach it for one reason or another?
I would rather be overwhelmed by the increase than think higher now and have my whelm well and truly undered if it dosent materialise.
Jadam post recommended
The poster obviously wants in or sold on Friday.
We await zebs thoughts.
Glorious day enjoy all :-)
Zeb I will help you with your 1st one it’s not hard if you go on the aim website.
on the junior market can cost a minimum of £500,000, while core running costs clock in at a minimum of £200,000 per year.
Zeb the 3 points you call out in your post.
I would imagine you have figures to throw weight behind your bullet points.
We are all ears and await your next post
Why are people ramping this so hard, makes people more suspicious than anything else
We have ludicrous claims
- 500k to list stemprint
- £2.5++ BILLION valuation
- £10 SP
Feels like there a load of noobs to AIM / investing making wild claims that are totally unfounded.